Business Description
Syndax Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US87164F1057
Description
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 475.87 | |||||
| Equity-to-Asset | 0.86 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 9.26 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -20.2 | |||||
| 3-Year EPS without NRI Growth Rate | -16.8 | |||||
| 3-Year FCF Growth Rate | -9.8 | |||||
| 3-Year Book Growth Rate | 7.4 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 47.49 | |||||
| 9-Day RSI | 41.74 | |||||
| 14-Day RSI | 41.3 | |||||
| 6-1 Month Momentum % | -7.54 | |||||
| 12-1 Month Momentum % | 21.12 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.99 | |||||
| Quick Ratio | 6.99 | |||||
| Cash Ratio | 6.84 | |||||
| Days Sales Outstanding | 77.72 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -21 | |||||
| Shareholder Yield % | 0.02 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -2007.58 | |||||
| Net Margin % | -1856.64 | |||||
| FCF Margin % | -1617.9 | |||||
| ROE % | -67.33 | |||||
| ROA % | -60.43 | |||||
| ROIC % | -690.96 | |||||
| ROC (Joel Greenblatt) % | -23780.52 | |||||
| ROCE % | -67.23 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 87.98 | |||||
| PB Ratio | 3.84 | |||||
| Price-to-Tangible-Book | 3.84 | |||||
| EV-to-EBIT | -3.38 | |||||
| EV-to-Forward-EBIT | -4.47 | |||||
| EV-to-EBITDA | -3.38 | |||||
| EV-to-Forward-EBITDA | -4.47 | |||||
| EV-to-Revenue | 62.68 | |||||
| EV-to-Forward-Revenue | 6.08 | |||||
| EV-to-FCF | -3.87 | |||||
| Price-to-Net-Current-Asset-Value | 3.96 | |||||
| Price-to-Net-Cash | 4.06 | |||||
| Earnings Yield (Greenblatt) % | -29.59 | |||||
| FCF Yield % | -18.37 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SNDX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Syndax Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 16 | ||
| EPS (TTM) ($) | -3.63 | ||
| Beta | 0.87 | ||
| Volatility % | 44.67 | ||
| 14-Day RSI | 41.3 | ||
| 14-Day ATR ($) | 1.057592 | ||
| 20-Day SMA ($) | 17.8825 | ||
| 12-1 Month Momentum % | 21.12 | ||
| 52-Week Range ($) | 15 - 25.34 | ||
| Shares Outstanding (Mil) | 85.36 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Syndax Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Syndax Pharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Syndax Pharmaceuticals Inc Frequently Asked Questions
What is Syndax Pharmaceuticals Inc(SNDX)'s stock price today?
The current price of SNDX is $16.51. The 52 week high of SNDX is $25.34 and 52 week low is $15.00.
When is next earnings date of Syndax Pharmaceuticals Inc(SNDX)?
The next earnings date of Syndax Pharmaceuticals Inc(SNDX) is 2025-02-27 Est..
Does Syndax Pharmaceuticals Inc(SNDX) pay dividends? If so, how much?
Syndax Pharmaceuticals Inc(SNDX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers